Clinical Trial

Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 22, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.
Trial Details
NCT Number NCT07296250
Lead Sponsor Chang Gung Memorial Hospital
Conditions Head and Neck Cancer, Oral Cancer
Enrollment 100 participants
Start Date 2025-08-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-22